Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients (LIBERATE)

  • End date
    Jun 24, 2038
  • participants needed
  • sponsor
    Quell Therapeutics Limited
Updated on 24 March 2022
liver transplant


The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of allograft rejection following immunosuppression withdrawal in liver transplantation. QEL-001 is a product made from a liver transplant recipient's own immune cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it.


This study is a multicenter, first-in-human, open-label, single-arm study of an autologous CAR T regulatory (CAR-Treg) in HLA-A2 mismatched liver transplant recipients. The aim is for the CAR-Tregs to be activated on recognition of HLA-A2 antigens present on the donated liver and subsequently induce and maintain immunological tolerance to the organ.

Condition Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Treatment QEL-001
Clinical Study IdentifierNCT05234190
SponsorQuell Therapeutics Limited
Last Modified on24 March 2022


Yes No Not Sure

Inclusion Criteria

Written informed consent
Subject who received HLA A2-mismatch liver transplant 12 months to 5 years prior to study entry
Able and willing to use contraception

Exclusion Criteria

Subjects with prior non-liver solid organ or hematopoietic stem cell transplant
Known hypersensitivity to study medication ingredients, protocol defined immunosuppressive medications, or a significant allergic reaction to any drug
Positive serology for human immunodeficiency virus (HIV), active or latent tuberculosis (TB) or other clinically active local or systemic infection
Use of investigational agents within 3 months
Subjects with history of autoimmune disease
Subject with history of malignancy in the past 5 years
Medical or social condition that is not compatible with adequate study follow-up and any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study
Protocol defined laboratory value for the following parameters
Alanine aminotransferase (ALT) and either alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT)
Kidney function e.g. eGFR
White blood cells
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note